No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Products Co., Ltd. was founded in 2004 and is based in Chengdu, China.
www.kangh.comNo one on the platform currently holds 300841.SZ.
No tracked institution reports a position in 300841.SZ as of their last filing.
No one on the platform has traded 300841.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.7% | 22.8% | — | — | — | |
| Rev. Growth % | -18.6% | 2.3% | ||||
| Profit Margin % | 18.9% | 36.9% | 32.1% | |||
| Free Cash Flow Margin % | 26.5% | 10.6% | 14.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +9.4% | $2.16 | $2.16–$2.16 | — | 1 |
| 2027 | $1.5B | +15.8% | $2.54 | $2.54–$2.54 | — | 1 |
| 2028 | $1.7B | +11.1% | $2.86 | $2.86–$2.86 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300841.SZChengdu Kanghua Biological Products Co., Ltd. | $49.31 | +0.67% | $6.4B | — |
| 000990.SZChengzhi Shareholding Co., Ltd. | $6.46 | +1.73% | $11.0B | — |
| 002030.SZDaan Gene Co., Ltd. | $5.22 | +0.19% | $7.3B | — |
| 301207.SZHualan Biological Bacterin Inc. | $18.06 | +0.89% | $10.7B | — |
| 603229.SSZhejiang Ausun Pharmaceutical Co., Ltd. |
| $7.55 |
| -0.13% |
| $6.3B |
| — |
| 605116.SSAurisco Pharmaceutical Co.,Ltd. | $19.01 | +0.21% | $7.7B | — |
| 688319.SSChengdu Olymvax Biopharmaceuticals Inc. | $26.86 | +0.15% | $10.9B | — |
Source: Financial Modeling Prep · peers by sector/industry